Abstract 3690
Background
With the success of immunotherapy in various solid cancers, the expression of programmed death-ligand 1 (PD-L1) in cancer cells has been attracting attention. The aim of this study was to analyze PD-L1 expression in resected UPS and evaluate its clinical impact.
Methods
All consecutive patients who were treated with UPS in Asan Medical Center, between January 1995 and December 2016, were retrospectively reviewed. PD-L1 staining was performed using SP263 antibody on their archived tissues. PD-L1 H-score was calculated by intensity (0-3) multiplied by proportion (0-100).
Results
A total of 176 patients with localized UPS who underwent curative-intent surgical resection were included in this study. There were 104 males (59.1%) and 72 females (40.9%), and the median age of patients was 59 years at the time of diagnosis. The most frequently involved primary site was extremities (84/176, 47.7%), followed by abdomen and pelvis (46/176, 26.1%), thorax (29/176, 16.5%), and head and neck (17/176, 9.7%). The PD-L1 analysis was available on slides from 114 (64.8%) patients and PD-L1 expression was observed in 83 (72.8%) cases. Intensity of staining varied between weak (44/83, 53.0%), intermediate (29/83, 34.9%), strong (10/83, 12.0%). Distribution of PD-L1 expression using different cut-off values were as follows: ≥1%: 83/114 (72.8%); ≥5%: 79/114 (69.3%); ≥10%: 52/114 (45.6%); ≥50%: 20/114 (17.5%). The 5-year disease free survival (DFS) rate seemed to be better in patients with PD-L1 positive than in patients with PD-L1 negative (56.5% vs 41.9%), but no statistical significant was observed (p = 0.183). There was a trend for better 5-year DFS rate with higher proportion of PD-L1 or higher PD-L1 H-score (proportion: 0% vs 1-49% vs ≥ 50, 41.9% vs 52.9% vs 70.1%, p = 0.098; H-score: 0 vs 1-100 vs ≥ 101, 41.9% vs 53.1% vs 75.7%, p = 0.087) without statistical singnificance.
Conclusions
In this study, PD-L1 protein expression was seen in substantial cases of resected UPS and it appeared to be a positive prognostic biomarker for longer DFS, although not statistically demonstrated. Further studies are needed comprehensively understand the impact of immune repertoire in UPS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1728 - A phase III trial evaluating olanzapine 5 mg for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin: J-FORCE Study
Presenter: Hironobu Hashimoto
Session: Poster Display session 1
Resources:
Abstract
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract